GMDA - Gamida Cell gains on long-term data for blood cancer therapy

• Israel-based biotech Gamida Cell Ltd. ( NASDAQ: GMDA ) announced Thursday that its stem cell therapy candidate omidubicel led to clinical benefit at three years in a group of patients with blood cancer who typically have a poor prognosis.
• The analysis included long-term follow-up data from 105 patients who underwent omidubicel transplants between 2006-2020.
• The company said that the study presented at the Annual Meeting of the Society of Hematologic Oncology indicated 63% overall survival and 56% disease-free survival at three years, in addition to long-term blood cell formation and immunity.
• Another 108-patient study demonstrated that omidubicel could lead to a higher health-related quality of life than umbilical cord blood transplantation .
• In August, GMDA announced that the FDA granted priority review for omidubicel as a treatment for patients with blood cancers who need an allogenic hematopoietic stem cell transplant. The regulator is expected to make a decision by Jan. 30.

For further details see: